Clinical Report: Predicting Alzheimer's Disease Diagnosis Through Comorbidity Patterns
Overview
This study identifies distinct longitudinal comorbidity patterns associated with Alzheimer's disease (AD) that differ by sex and APOE genotype. The findings suggest that understanding these patterns may aid in precision prevention strategies for AD.
Background
Alzheimer's disease is a leading cause of dementia, affecting millions globally. The interplay between non-modifiable factors, such as age and genetics, and modifiable comorbidities like hypertension and diabetes, is crucial in understanding AD risk. Identifying how these factors interact over time can inform better prevention and treatment strategies.
Data Highlights
Finding
Percentage
p-value
Hypertension-preceding-AD in females
7.0%
0.005
Hypertension-preceding-AD in males
3.8%
0.005
Males with metabolic-vascular patterns
7.7%
0.0085
Females with metabolic-vascular patterns
4.5%
0.0085
APOE-ε4 carriers with accelerated multi-comorbidity
Not specified
1 × 10−4
Key Findings
203 distinct comorbidity sequences identified across 7,316 clinical events.
Females exhibited hypertension-preceding-AD sequences more frequently than males (7.0% vs. 3.8%).
Males showed earlier metabolic-vascular patterns involving hyperlipidemia and hypertension (7.7% vs. 4.5%).
APOE-ε4 carriers had accelerated multi-comorbidity patterns compared to non-carriers.
External validation confirmed sex-specific patterns across 191 sequences and 5,176 events.
Clinical Implications
Understanding the distinct comorbidity patterns associated with Alzheimer's disease can help healthcare professionals identify at-risk populations. This knowledge may lead to targeted interventions and improved management strategies for individuals with multiple risk factors.
Conclusion
The study highlights the importance of considering sex and APOE genotype in the assessment of comorbidity patterns preceding Alzheimer's disease, which may inform future prevention strategies.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
